Vosaroxin for relapsed AML: Updates from VALOR

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Venetoclax plus cytarabine in elderly AML patients

Intravenous or subcutaenous rituximab for FL in the SABRINA study

Ibrutinib in CLL: RESONATE and resistance

Large granular lymphocyte proliferations in MDS

Durable remissions with the VcR-CVAD regimen for MCL regardless of age

Tailoring therapy for leukaemia patients

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

Dose reduction of TKIs for CML patients with deep molecular response

Updates from the EURO-SKI trial of tyrosine kinase cessation

CML patients with stable response may safely decrease dose of TKI